(MPT) Medical Properties Trust - Overview
Sector: Real Estate | Industry: REIT - Healthcare Facilities | Exchange: NYSE (USA) | Market Cap: 3.038m USD | Total Return: 22.4% in 12m
Avg Turnover: 26.9M
Qual. Beats: 0
Rev. Trend: -28.0%
Warnings
High Debt/EBITDA (8.2) with thin interest coverage (1.4)
High Debt while negative Cash Flow
Altman Z'' -0.87 < 1.0 - financial distress zone
Fakeout Choppy Below Avwap Earnings
Tailwinds
Confidence
Medical Properties Trust, Inc. (NYSE: MPT) is a self-advised real estate investment trust (REIT) focused on the acquisition and development of net-leased hospital facilities. Founded in 2003 and headquartered in Birmingham, Alabama, the company manages a global portfolio of 388 facilities across nine countries and three continents. Its business model utilizes sale-leaseback transactions, which allow hospital operators to convert real estate into liquid capital for operational improvements and technology upgrades.
The company operates within the Health Care REIT sector, specifically targeting acute care, rehabilitation, and behavioral health properties. Under a triple-net lease structure, the tenant is typically responsible for all property-related expenses, including taxes, insurance, and maintenance, which provides the REIT with a more predictable revenue stream. For a deeper look into the companys valuation metrics, investors may find further analysis on ValueRay useful. Hospital real estate remains a critical infrastructure asset class, often characterized by long-term lease agreements and high barriers to entry due to specialized regulatory requirements.
- Tenant credit risk and restructuring outcomes impact rental income stability
- Interest rate fluctuations dictate debt refinancing costs and AFFO margins
- Asset divestitures and liquidity management drive balance sheet deleveraging progress
- Medicare and Medicaid reimbursement changes affect hospital operator profitability
- Global healthcare real estate demand influences portfolio occupancy and valuation
| Net Income: -126.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA 5.67 > 1.0 |
| NWC/Revenue: 14.06% < 20% (prev 48.68%; Δ -34.62% < -1%) |
| CFO/TA 0.01 > 3% & CFO 216.1m > Net Income -126.2m |
| Net Debt (9.44b) to EBITDA (1.15b): 8.23 < 3 |
| Current Ratio: 1.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (597.7m) vs 12m ago -0.48% < -2% |
| Gross Margin: 82.13% > 18% (prev 0.97%; Δ 8.12k% > 0.5%) |
| Asset Turnover: 6.75% > 50% (prev 6.41%; Δ 0.35% > 0%) |
| Interest Coverage Ratio: 1.36 > 6 (EBITDA TTM 1.15b / Interest Expense TTM 641.0m) |
| A: 0.01 (Total Current Assets 1.35b - Total Current Liabilities 1.21b) / Total Assets 14.8b |
| B: -0.28 (Retained Earnings -4.16b / Total Assets 14.8b) |
| C: 0.06 (EBIT TTM 874.4m / Avg Total Assets 14.8b) |
| D: -0.39 (Book Value of Equity -4.03b / Total Liabilities 10.2b) |
| Altman-Z'' = -0.87 = CCC |
| DSRI: 0.96 (Receivables 922.1m/909.6m, Revenue 1.00b/951.5m) |
| GMI: 1.18 (GM 82.13% / 96.90%) |
| AQI: 1.11 (AQ_t 0.16 / AQ_t-1 0.14) |
| SGI: 1.05 (Revenue 1.00b / 951.5m) |
| TATA: -0.02 (NI -126.2m - CFO 216.1m) / TA 14.8b) |
| Beneish M = -2.82 (Cap -4..+1) = A |
As of June 02, 2026, the stock is trading at USD 4.99 with a total of 6,031,804 shares traded.
Over the past week, the price has changed by -0.97%,
over one month by +3.44%,
over three months by -7.88% and
over the past year by +22.40%.
Medical Properties Trust has no consensus analysts rating.
P/E Forward = 6.6667
P/S = 2.7624
P/B = 0.6685
P/EG = 1.6083
Revenue TTM = 1.00b USD
EBIT TTM = 874.4m USD
EBITDA TTM = 1.15b USD
Long Term Debt = 9.00b USD (from longTermDebt, last quarter)
Short Term Debt = 102.5m USD (from shortTermDebt, last quarter)
Debt = 9.87b USD (from shortLongTermDebtTotal, last quarter) + Leases 102.5m
Net Debt = 9.44b USD (calculated: Debt 9.87b - CCE 425.0m)
Enterprise Value = 12.5b USD (3.04b + Debt 9.87b - CCE 425.0m)
Interest Coverage Ratio = 1.36 (Ebit TTM 874.4m / Interest Expense TTM 641.0m)
EV/FCF = -32.44x (Enterprise Value 12.5b / FCF TTM -384.7m)
FCF Yield = -3.08% (FCF TTM -384.7m / Enterprise Value 12.5b)
FCF Margin = -38.46% (FCF TTM -384.7m / Revenue TTM 1.00b)
Net Margin = -12.61% (Net Income TTM -126.2m / Revenue TTM 1.00b)
Gross Margin = 82.13% ((Revenue TTM 1.00b - Cost of Revenue TTM 178.8m) / Revenue TTM)
Gross Margin QoQ = 40.74% (prev none%)
Tobins Q-Ratio = 0.85 (Enterprise Value 12.5b / Total Assets 14.8b)
Interest Expense / Debt = 6.50% (Interest Expense 641.0m / Debt 9.87b)
Taxrate = 21.0% (US default 21%)
NOPAT = 690.8m (EBIT 874.4m * (1 - 21.00%))
Current Ratio = 0.83 (Total Current Assets 1.35b / Total Current Liabilities 1.62b)
Debt / Equity = 2.17 (Debt 9.87b / totalStockholderEquity, last quarter 4.54b)
Debt / EBITDA = 8.23 (Net Debt 9.44b / EBITDA 1.15b)
Debt / FCF = -24.54 (negative FCF - burning cash) (Net Debt 9.44b / FCF TTM -384.7m)
Total Stockholder Equity = 4.66b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.85% (Net Income -126.2m / Total Assets 14.8b)
RoE = -1.43% (Net Income TTM -126.2m / Total Stockholder Equity 8.82b)
RoCE = 4.91% (EBIT 874.4m / Capital Employed (Equity 8.82b + L.T.Debt 9.00b))
RoIC = 4.82% (NOPAT 690.8m / Invested Capital 14.3b)
WACC = 5.58% (E(3.04b)/V(12.9b) * Re(7.04%) + D(9.87b)/V(12.9b) * Rd(6.50%) * (1-Tc(0.21)))
Discount Rate = 7.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 51.11 | Cagr: -0.09%
[DCF] Fair Price = unknown (Cash Flow -384.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.11 | # QB: 0
Revenue Correlation: -27.99 | Revenue CAGR: -7.03% | SUE: N/A | # QB: 0
EPS next Quarter (2026-09-30): EPS=0.04 | Chg30d=N/A | Revisions=+20% | Analysts=1
EPS current Year (2026-12-31): EPS=0.11 | Chg30d=+37.50% | Revisions=-20% | GrowthEPS=+0.0% | GrowthRev=+6.6%
EPS next Year (2027-12-31): EPS=0.17 | Chg30d=+22.22% | Revisions=N/A | GrowthEPS=+50.0% | GrowthRev=+5.8%
[Analyst] Revisions Ratio: +20%